Harmony Biosciences Holdings Forecast, price target & analysts
Harmony Biosciences Holdings Target price 2025 - Analyst rating & recommendation
Harmony Biosciences Holdings Classifications & Recommendation:
Harmony Biosciences Holdings Price Target
| Target Price | $51.67 |
| Price | $32.75 |
| Potential |
57.76%
register free of charge
|
| Number of Estimates | 9 |
|
9 Analysts have issued a price target Harmony Biosciences Holdings 2026 .
The average Harmony Biosciences Holdings target price is $51.67.
This is
57.76%
register free of charge
$70.00
113.74%
register free of charge
$33.00
0.76%
register free of charge
|
|
| A rating was issued by 9 analysts: 8 Analysts recommend Harmony Biosciences Holdings to buy, 0 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Harmony Biosciences Holdings stock has an average upside potential 2026 of
57.76%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 714.73 | 842.37 |
| 22.80% | 17.86% | |
| EBITDA Margin | 30.07% | 36.60% |
| 19.11% | 21.70% | |
| Net Margin | 20.07% | 20.21% |
| 4.04% | 0.72% |
9 Analysts have issued a sales forecast Harmony Biosciences Holdings 2025 . The average Harmony Biosciences Holdings sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Harmony Biosciences Holdings EBITDA forecast 2025. The average Harmony Biosciences Holdings EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
9 Harmony Biosciences Holdings Analysts have issued a net profit forecast 2025. The average Harmony Biosciences Holdings net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 2.51 | 2.98 |
| 17.84% | 18.73% | |
| P/E | 10.99 | |
| EV/Sales | 1.95 |
9 Analysts have issued a Harmony Biosciences Holdings forecast for earnings per share. The average Harmony Biosciences Holdings <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2025, the Harmony Biosciences Holdings stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Harmony Biosciences Holdings...
Current Harmony Biosciences Holdings Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Feb 27 2025 |
| Needham | Locked ➜ Locked | Locked | Feb 26 2025 |
| Needham | Locked ➜ Locked | Locked | Feb 25 2025 |
| Mizuho | Locked ➜ Locked | Locked | Feb 20 2025 |
| Needham | Locked ➜ Locked | Locked | Feb 19 2025 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Feb 19 2025 |
| Deutsche Bank | Locked ➜ Locked | Locked | Feb 11 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Feb 27 2025 |
|
Locked
Needham: Locked ➜ Locked
|
Feb 26 2025 |
|
Locked
Needham: Locked ➜ Locked
|
Feb 25 2025 |
|
Locked
Mizuho: Locked ➜ Locked
|
Feb 20 2025 |
|
Locked
Needham: Locked ➜ Locked
|
Feb 19 2025 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Feb 19 2025 |
|
Locked
Deutsche Bank: Locked ➜ Locked
|
Feb 11 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
